Editorial

Editorial

• Güven Aslan

Bph

Metabolic syndrome in the etiology of benign prostatic hyperplasia/ lower urinary tract symptoms

• Polat Türker
• Cenk M. Yazıcı

The current status of prostate-specific antigen in the management of Benign Prostatic Hyperplasia

• Ali Tekin

Urodynamic studies in Benign Prostate Hyperplasia: whom and when?

• Umut Gönülalan
• Murat Koşan

The role of phosphodiesterase type-5 inhibitors in Benign Prostatic Hyperplasia, current approaches

• Eray Kemahlı
• Adnan Gücük
• Uğur Üyetürk

Prostatic inflammation as a target of etiopathogenesis and treatment

• Murat Koşan
• Umut Gönülalan

The combination of anticholinergics and alpha-1 receptor blockers

• Yusuf Şenoğlu
• Kamil Çam

Will lasers replace transurethral resection of the prostate for the treatment of BPH?

• Ali Erol
• Serhat Dönmezer
• Erem Kaan Başok

Long-term treatment of Benign Prostatic Hyperplasia with the combination of alpha blockers and 5-alpha reductase inhibitors

• Cevahir Özer
• Mehmet İlteriş Tekin

Quality Of Life

The impact of control cystoscopies' on quality of life in the surveillance of bladder tumor

• İlker Çelen

The comparison of the treatment alternatives on quality of life in testicular cancers

• Sinharib Çitgez
• Çetin Demirdağ
• Kamil Çam

Does laser prostatectomy provide an advantage regarding quality of life?

• Olcay Yıldırım
• Kamil Çam

Pathology

Prostate cancer: New developments in pathogenesis and prognostic repercussions

• Bora Gürel

Evaluation of the non-neoplastic kidney in tumor nephrectomy specimens and its significance

• Ayşim Özağarı

General

Basic molecular methods used in urooncology

• Bora İrer
• Güven Aslan